中文
 

Follow us 

Hot Topic
Market News
Events & Promo
Career Tips
Education News
Health & Life
Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026
PRNewswire

Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

Publish date: 27 Oct 2026

Follow us

Stay updated on the job market

Popular Articles

【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」

SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first nine months of 2026. During this period, Hengrui reported revenue of RMB24.41 billion, representing a year-over-year increase of 5.26%. Product sales revenue was RMB21.48 billion, up 2.52% year-over-year. Net profit attributable to shareholders of the Company was RMB6.92 billion, up 20.38% year-over-year.

Innovative drug sales reached RMB13.87 billion, representing a year-over-year increase of 17.05% and accounting for approximately 64.59% of total drug sales. Non-oncology innovative drug sales also recorded strong growth, reaching RMB4.01 billion, up 75.36% year-over-year, and accounting for approximately 28.88% of total innovative drug sales. R&D investment totaled RMB7.15 billion, of which RMB5.42 billion was expensed.

In the third quarter of 2026, Hengrui reported revenue of RMB8.95 billion, up 20.55% year-over-year, and net profit attributable to shareholders of the Company of RMB2.46 billion, up 88.92% year-over-year.

Pipeline and Regulatory Highlights

In the third quarter of 2026, Hengrui continued to advance its R&D pipeline in China, obtaining seven innovative drug or indication approvals comprising two Class 1 innovative drugs and five new indications for marketed innovative drugs.

Seven marketing applications were also accepted for review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration, covering oncology, metabolic and cardiovascular diseases, immune system diseases, and neuroscience. Notably, the Company made multiple advancements across the GLP-1 class product pipeline. The new drug applications (NDAs) for HRS-7535 tablets, an oral small-molecule GLP-1 receptor agonist, for glycemic control in adults with type 2 diabetes mellitus and for long-term weight management in adults have both been accepted for review. The NDA for ribupatide injection, a GLP-1/GIP dual receptor agonist for glycemic control in adults with type 2 diabetes mellitus, has also been accepted for review.

In addition, a total of 35 clinical trial approvals were obtained. Two products have been granted Breakthrough Therapy Designation by the CDE.

Global Partnerships and Business Development

In the first nine months of 2026, the Company recorded revenue of RMB2.78 billion from the out-licensing of innovative drugs, up 31.12% year-over-year. Hengrui also received a total of RMB4.34 billion in cash from upfront and milestone payments under collaboration agreements, primarily comprising the US$600 million upfront payment from Bristol Myers Squibb.

On September 29, Hengrui entered into a license agreement with Novo Nordisk (Novo) for HRS-1596, a phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing. Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding the Chinese mainland, the Hong Kong SAR, the Macao SAR and Taiwan Region. The potential total value of the agreement is up to US$2.6 billion contingent on the achievement of applicable development, regulatory and commercial milestones. This includes a US$300 million upfront payment. In addition, Hengrui is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory. The transaction is expected to close in the fourth quarter of 2026.

Scientific Recognition

Since the start of the second half of 2026, multiple research findings on Hengrui's innovative drugs have been presented at international academic conferences and published in academic journals. More than 60 studies involving 21 innovative drugs were selected for presentation at the European Society for Medical Oncology Congress 2026, including Phase III studies of two innovative antibody-drug conjugates selected for Proffered Paper presentations. Research in non-oncology areas was also presented at major international congresses, including the Annual Meeting of the European Association for the Study of Diabetes and the European Academy of Dermatology and Venereology Congress, among others.

Outlook

Looking ahead, Hengrui will continue to advance its innovation and globalization strategy, further pursuing its dual-growth strategy across oncology and chronic diseases. Guided by its patient-focused philosophy, Hengrui remains committed to bringing more innovative medicines to patients worldwide.

Follow us

Stay updated on the job market

Popular Articles

【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」

Hottest Tags

#馬斯克
#Elon Musk
#香港出生率
#少子化危機
#出生人口下跌
#生育津貼
#人口老化
#育兒成本
#打工仔減肥
#過勞肥
#辦公室致肥習慣
#寫字樓減肥

Viewed jobs
Room Attendant Hopewell Hotel 合和酒店
14 days ago
中醫師 Tung Wah Group of Hospitals
14 days ago
Police Inspector Hong Kong Police
14 days ago
Police Constable Hong Kong Police
14 days ago
Police Mentorship Programme – Recruitment of mentees Hong Kong Police
14 days ago
Viewed jobs
Contact Us
Notice
Back to Top
We use cookies to enhance your experience on our website. Please read and confirm your agreement to our Privacy Policy and Terms and Conditions before continue to browse our website. Read and Agreed